TerminatedPhase 3NCT00712426
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
Studying Huntington's Disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Steven M Hersch, MD, PhDMassachusetts General Hospital
- Intervention
- Creatine Monohydrate(drug)
- Enrollment
- 553 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2009 – 2015
Study locations (30)
- University of Alabama, Birmingham, Alabama, United States
- University of California, Irvine, Irvine, California, United States
- University of California Davis, Sacramento, California, United States
- University of Connecticut, Farmington, Connecticut, United States
- University of Florida (McKnight Brain Institute), Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Georgia Regents University, Augusta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Iowa, Iowa City, Iowa, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- Hereditary Neurological Disease Center (HNDC), Wichita, Kansas, United States
- University of Louisville, Louisville, Kentucky, United States
- University of Maryland School of Medicine, Baltimore, Maryland, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
University of Rochester · National Center for Complementary and Integrative Health (NCCIH)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00712426 on ClinicalTrials.govOther trials for Huntington's Disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07246941A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's DiseaseHoffmann-La Roche
- RECRUITINGNANCT06807892Comparison of Two Cognitive-Motor Rehabilitation Approaches Via Exergames: a Study of Cognitive, Motor and Behavioral Functions in Huntington's Disease PatientsUniversity Hospital, Angers
- RECRUITINGNANCT07299682Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self Feeding Behaviours in a Huntington's Disease PopulationUniversity of Hull
- RECRUITINGPHASE1NCT06585449A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's DiseaseAlnylam Pharmaceuticals
- ACTIVE NOT RECRUITINGNCT07503743Biology-Driven Cognitive Profiling in Huntington's DiseaseFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04120493Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's DiseaseUniQure Biopharma B.V.
- RECRUITINGNCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's DiseaseUniversity College, London
- RECRUITINGNCT01574053Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease CohortCHDI Foundation, Inc.